Genmab A/S (Genmab A/S) Change In Inventory : $0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Genmab A/S Change In Inventory?

Genmab A/S's change in inventory for the quarter that ended in Dec. 2023 was $0 Mil. It means Genmab A/S's inventory stayed the same from Sep. 2023 to Dec. 2023 .

Genmab A/S's change in inventory for the fiscal year that ended in Dec. 2023 was $-8 Mil. It means Genmab A/S's inventory increased by $8 Mil from Dec. 2022 to Dec. 2023 .

Genmab A/S's Total Inventories for the quarter that ended in Dec. 2023 was $8 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Genmab A/S's Days Inventory for the quarter that ended in Dec. 2023 was 45.43.

Inventory Turnover measures how fast the company turns over its inventory within a year. Genmab A/S's Inventory Turnover for the quarter that ended in Dec. 2023 was 2.01.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Genmab A/S's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.01.

Genmab A/S Change In Inventory Historical Data

The historical data trend for Genmab A/S's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab A/S Change In Inventory Chart

Genmab A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Get a 7-Day Free Trial

-8.34

Genmab A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Genmab A/S Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

Genmab A/S (NAS:GMAB) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Genmab A/S's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	9.179	/	18.435	*	365 / 4
	=	45.43

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Genmab A/S's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	18.435	/	9.179
	=	2.01

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Genmab A/S's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	9.179	/	684.438
	=	0.01

Genmab A/S Change In Inventory Related Terms

Thank you for viewing the detailed overview of Genmab A/S's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab A/S (Genmab A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (NAS:GMAB) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

GNMSF:USA GMAB:Mexico GMABc:UK 0MGB:UK GMAB:Denmark GE91:Germany GE91:Germany GE9:Germany

Address

Kalvebod Brygge 43, Copenhagen, DNK, 1560

Website

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.